权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of double transplant strategy for the treatment of intractable leukemias in children

儿童难治性白血病双移植策略的制定

基本信息

批准号：
16591044
负责人：
KAWANO Yoshifumi
金额：
$ 2.24万
依托单位：
Kagoshima University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2006
项目状态：
已结题

项目摘要

The purpose of this research is to establish an effective treatment strategy for pediatric cancer patients with tandem high-dose chemotherapy followed by hematopoietic stem cell transplantation, especially with purified CD133-positive cells.Since data of purified CD133-positive cells has not been reported in pediatric field, we started to use purified CD133-positive cells as a graft in an autologous setting and the usefulness of CD133-positive cells was confirmed. To reduce the toxicity of high-dose chemotherapy before transplantation, we divided it into two parts both that were followed by stem cell transplantation. Although the number of transplanted patients has not reached at the level of reliable analysis, we showed the limitation of current high-dose chemotherapy, by which residual tumor cells could not be eradicated in intractable cases. In addition to this, we also confirmed that allo-immune reaction could not suppress the proliferation of malignant tumor cells, which had not been controlled by conventional chemotherapy.From the study, we suggested that the purified CD133-positive cells could be used as auto-graft at the first transplantation for the treatment of very high-risk pediatric cancer patients and as allograft for the purpose of an additional infusion in patients with late engraftment failure, whereas the most useful strategy using purified CD133-positve cells should be clarified by future cohort studies.

本研究的目的是为儿科癌症患者建立一种有效的治疗策略，先进行串联大剂量化疗，然后进行造血干细胞移植，特别是纯化的CD133阳性细胞。由于儿科领域尚未报道纯化的CD133阳性细胞的数据，我们开始在自体环境中使用纯化的CD133阳性细胞作为移植物，以及CD133阳性细胞的用途细胞得到确认。为了减少移植前大剂量化疗的毒性，我们将其分为两部分，然后进行干细胞移植。尽管移植患者的数量尚未达到可靠分析的水平，但我们显示了当前大剂量化疗的局限性，对于难治性病例，无法根除残留的肿瘤细胞。除此之外，我们还证实，同种免疫反应不能抑制常规化疗无法控制的恶性肿瘤细胞的增殖。从研究中，我们建议纯化的CD133阳性细胞可以作为自体移植物用于首次移植，用于治疗极高风险的儿科癌症患者，也可以作为同种异体移植物用于晚期植入失败患者的额外输注，而使用纯化的 CD133 阳性细胞的最有用策略应通过未来的队列研究来阐明。

项目成果

期刊论文数量（20）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor

粒细胞集落刺激因子单独动员外周血干细胞以及儿童和青少年实体瘤自体移植后的植入动力学

DOI：
发表时间：
2006
期刊：
Bone Marrow Transplantation(http://www.nature.com/doifinder/10.1038/sj.bmt.1705304)
影响因子：
0
作者：
Ito M;Ohmori I;Nakahori T et al.;Burioka N et al.;Hiroyoshi Watanabe
通讯作者：
Hiroyoshi Watanabe

Peripheral blood stem call mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.

单独粒细胞集落刺激因子的外周血干动员以及患有实体瘤的儿童和青少年自体移植后的植入动力学。